InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,868.40
(
-0.79%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
86.99
(
-0.27%
)
Bitcoin
64,253.96
(
-0.04%
)
Post# of 251590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RockRat post# 221543

Monday, 10/22/2018 5:04:23 PM

Monday, October 22, 2018 5:04:23 PM

Post# of 251590
NTGN—I concur with the viewpoint in your Twitter link, even while recognizing that the tweeter is an executive at a potentially competing company. Not testing monotherapy in phase-1 is curious, to say the least.

A cynic might say that NTGN didn’t examine NEO-PV-1 single-agent activity because they did not expect any, based on preclinical data.

Meanwhile… GRTS is hovering close to its IPO price after the unexplained pop last week.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up